fda ruling on compounded semaglutide Manufacturing Ban FDA warns about compounded versions

Remember, missing a single dose is unlikely to cause any serious harm, but try to establish a consistent routine going forward, to ensure the medication is as effective as possible

For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission

Patients should be educated to recognize concerning features that may indicate complications requiring clinical assessment

According to an agency press release issued Tuesday, the enforcement action centers on telehealth firms that marketed compounded versions of semaglutide, tirzepatide and liraglutide products, in ways that suggested equivalence with FDA-approved therapies such as Wegovy, Ozempic, Mounjaro and Zepbound

[1] [2] Other serious risks include pancreatitis, gallbladder disease, acute kidney injury, and hypersensitivity reactions

This suggests combination use is unlikely to trigger dangerous drug interactions